Beam Therapeutics Q3 2026 net loss widens 19% to $134.41 million

• Beam Therapeutics’ third-quarter 2026 net loss widened 19% year over year to $134.41 million.
• License and collaboration revenue fell 97% to $307,000, while general and administrative expenses rose 18% to $31.52 million year over year.
• September-end cash, cash equivalents and marketable securities totaled $1.04 billion; projected runway into mid-2029 assumes additional borrowing.
• A U.S. biologics license application for sickle cell therapy risto-cel is expected as early as year-end 2026.
• Completion of dosing in BEAM-302’s global pivotal cohort for alpha-1 antitrypsin deficiency is expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868726) on November 03, 2026, and is solely responsible for the information contained therein.